Amgen not precluded by invalidity decision under pre-amended PMNOC Regulations from litigating same patent under amended regulations

Published date04 November 2019
Subject MatterAppeals,Abuse of Process,Pfizer,Patent Litigation,Pharmaceutical Patents,Amgen,Canada,Amended Regulation,Apotex,Patent Invalidity,PMNOC Regulations
AuthorAbigail Smith
Law FirmSmart & Biggar

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT